Pet Cancer Therapeutics Market – By Species, By Therapy, By Route of Administration, By Cancer Type – Global Forecast, 2025 to 2034

Pet Cancer Therapeutics Market Size

The pet cancer therapeutics market size was valued at USD 477.1 million in 2024 and is estimated to grow at a CAGR of 9.7% from 2025 to 2034. The market is experiencing significant growth driven by the growing trend of pet humanization, with owners increasingly investing in comprehensive healthcare for their pets.
 

According to the 2023-2024 American Pet Products Association (APPA) National Pet Owners Survey, 66% of U.S. households, equating to approximately 87 million families, have a pet. This includes 65 million dogs and 46.5 million cats. The survey highlighted significant spending on pet healthcare, with the average American projected to spend USD 37 billion on veterinary care in 2023. This underscored the increasing prioritization of pet health and wellness in the U.S., reflecting pet owner's concern to regular and advanced veterinary care.
 

In addition, enhanced diagnostic capabilities and advanced treatment options, including targeted therapies and immunotherapies, have expanded access to effective cancer care. Additionally, an ageing pet population has led to higher cancer incidence rates, further propelling demand for veterinary oncology solutions. This shift in consumer behaviour, coupled with innovations in veterinary medicine, is driving the market's growth as pet owners seek high-quality, life-extending treatments for their animals.
 

Pet cancer therapeutics refer to a range of treatments developed to diagnose, manage, and treat cancers in animals, particularly in dogs, cats and other pets. This therapeutics includes chemotherapy, targeted therapies, immunotherapies, and other combination therapies aimed at reducing tumour size, alleviating symptoms, and prolonging pet health.
 

Pet Cancer Therapeutics Market Trends

Advancements in veterinary oncology are driving market growth by introducing innovative and targeted treatments that improve outcomes in pet cancer care. Developments such as precision therapies, advanced diagnostics, and immunotherapy offer more effective and less invasive options, leading to improved survival rates for pets with cancer. This progress is significantly contributing to the overall expansion of the market.
 

• For instance, in October 2024, Calviri, a biotech firm specializing in cancer vaccines for dogs and humans, has initiated a clinical trial for its investigational immunotherapy vaccine in canines with early-stage hemangiosarcoma (HSA). The Scout Out Canine Hemangiosarcoma (SOCH) study aimed to assess whether the "pre-made" vaccine, combined with standard treatments like surgery and chemotherapy, can extend the lifespan of dogs with stage 1 or 2 HSA by stimulating the immune system to target cancer cells. This trial launch aimed to lead to significant advancements in canine cancer care.
   
• Moreover, factors such as high treatment costs, regulatory hurdles, a shortage of specialized veterinary professionals, and limited awareness in developing regions are expected to hinder the market's growth.
   

Pet Cancer Therapeutics Market Analysis

Based on species, the global market is segmented into dogs, cats and other species. The dogs segment dominated the market and was valued at USD 402 million in 2024.
 

• The prominence of the dog segment is attributed to the higher incidence of cancer in dogs compared to other pets.
   
• As companion animals, dogs are more frequently diagnosed with cancers such as lymphoma, osteosarcoma, and mammary tumors, leading to an increased demand for therapeutic treatments.
   
• For instance, according to the Veterinary Cancer Society, cancer is the leading cause of death in 47% of dogs, particularly those over the age of ten. This statistic highlights the growing prevalence of cancer in older dogs, underscoring the increasing demand for cancer treatments. This growing need, especially in the aging dog population, is expected to significantly boost the market.
   
• Additionally, advancements in veterinary oncology, including more effective treatments and early detection techniques, have driven the growth of this segment.
   
• Furthermore, the growing awareness among pet owners about cancer in dogs, along with the availability of specialized therapies, significantly contributes to the dominance of the dog segment in this market.
   
• Lymphoma, a common cancer in dogs, has spurred research and drug approvals, such as the U.S. FDA’s 2021 approval of Tanovea (rabacfosadine injection). Additionally, ongoing clinical trials, such as Calviri, Inc.’s 2022 Vaccine Against Canine Cancer Study (VACCS) involving 800 dogs, highlight expanding awareness and therapeutic opportunities in the canine cancer segment for the forecast period.
   

Based on the therapy, the global pet cancer therapeutics market is segmented into chemotherapy, immunotherapy, targeted therapy, and combination therapy. The chemotherapy segment accounted for the highest market share of 62.1% in 2024.
 

• Chemotherapy effectively targets and kills cancer cells or inhibits their growth, making it a standard modality for various cancers, including lymphoma and mast cell tumors.
   
• As reported in several studies, the effectiveness of chemotherapy is highlighted by its ability to achieve remission in over 80% of cases, particularly for conditions like lymphoma, which are prevalent in dogs.
   
• As the market continues to grow, driven by increasing pet ownership and awareness of animal health, chemotherapy remains a cornerstone in veterinary oncology, providing vital treatment options for affected pets.
   

Based on the route of administration, the global pet cancer therapeutics market is segmented into oral and injection. The injection segment dominated the market in 2024 and is anticipated to reach USD 789 million by 2034.
 

• The preference for injections stems from their effectiveness in delivering cancer treatments directly into the bloodstream or at the tumor site.
   
• Injectable therapies, such as chemotherapy agents and immunotherapies, provide rapid absorption and targeted effects, making them particularly effective for treating a range of cancers in pets.
   
• These treatments are favored for their precision and superior management of side effects.
   
• With ongoing advancements in injectable formulations, the demand for injectable cancer therapeutics in veterinary care is anticipated to remain robust, further propelling the growth and dominance of this segment in the market.
   

Based on cancer type, the global pet cancer therapeutics market is segmented into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer, and other cancer types. The mast cell cancer segment is expected to grow at a 9.4% CAGR over the analysis period.
 

• The prominence of the mast cell cancer segment is attributed to the high prevalence of mast cell tumors in dogs, particularly in certain breeds like Boxers, Bulldogs, and Retrievers.
   
• Mast cell tumors are among the most common skin cancers in pets, and their aggressive nature often necessitates immediate and specialized treatment.
   
• For instance, according to the Morris Animal Foundation, mast cell tumors account for 16% to 21% of all skin tumors in pets. These tumors can vary in appearance and behavior, ranging from slow-growing, isolated masses to ulcerated, itchy, and diffuse lesions.
   
• Their prevalence, along with the potential for malignancy and complications, has contributed to the dominance of the mast cell cancer segment in the market.
   

In 2024, the U.S. held a significant position in the North American pet cancer therapeutics market and projected to dominate throughout the forecast period with a CAGR of 9.3%.
 

• The U.S. prominence was driven by its advanced veterinary healthcare infrastructure, high pet ownership rates, and increasing awareness of cancer treatments for pets.
   
• The country invests heavily in veterinary oncology, benefiting from cutting-edge technologies, research, and a broad array of treatment options, including chemotherapy, immunotherapy, and targeted therapies.
   
• Furthermore, the rising incidence of pet cancers, particularly among aging pets, further fuels demand for these therapeutics.
   
• Additionally, the presence of leading veterinary pharmaceutical companies and animal health clinics further solidified the U.S.'s role as the key driver of market growth in North America.
   

The pet cancer therapeutics market in Germany is estimated to grow at significant growth rate over the next few years.
 

• Germany's growth in the market is driven by factors such as increasing awareness of pet health, advancements in veterinary oncology, and a rising demand for specialized cancer treatments.
   
• For instance, according to Der Deutsche Heimtiermarkt in 2021, 47% of German households owned pets, with 34.7 million dogs, cats, small animals, and birds. The growing pet ownership has led to heightened awareness of pet health, resulting in increased spending on veterinary care and cancer therapeutics.
   
• As cancer is a leading cause of death in pets, this trend is expected to boost demand for cancer diagnostics and treatments, with ongoing research further supporting market growth in Germany.
   

China held the prominent position in the Asia Pacific pet cancer therapeutics market during the analysis period.
 

• China’s growth was driven by the increasing incidence of pet cancer, elevated awareness among pet owners and veterinarians regarding effective treatments, and advancements in veterinary medicine.
   
• The country's robust biotechnology sector and supportive government policies further enhance its attractiveness for therapeutic manufacturing in veterinary oncology.
   
• In addition, as domestic companies innovate and produce affordable cancer treatments, China is also positioned as a key exporter of veterinary therapeutics, contributing to its influence in the animal healthcare market, which was valued at USD 186.1 billion in 2023.
   

Brazil pet cancer therapeutics market is anticipated to witness high growth over the analysis timeframe in Latin America.
 

• Increasing pet ownership, coupled with rising awareness of cancer treatment options, is driving demand for advanced veterinary care in the country.
   
• In addition, the growing recognition of the specialized oncology treatments for pets, such as chemotherapy, immunotherapy, and targeted therapies, is contributing to the market’s expansion.
   
• Additionally, Brazil's expanding veterinary healthcare infrastructure, along with the availability of more effective cancer therapeutics, is likely to enhance access to these treatments.
   
• Therefore, the aforementioned factors witnessed the Brazil’s prominence in the Latin America market.
   

Saudi Arabia is anticipated to grow in the Middle East and African pet cancer therapeutics market.

• Saudi Arabia's increasing pet ownership, particularly among affluent urban populations, is driving demand for advanced veterinary care.
   
• As awareness of pet health and cancer treatment options rises, more pet owners are seeking specialized cancer therapies such as chemotherapy and immunotherapy.
   
• Additionally, Saudi Arabia's expanding veterinary healthcare infrastructure, along with investments in research and development, are improving access to cutting-edge treatments.
   
• These developments position Saudi Arabia as a key market in the region for pet cancer therapeutics over the forecast period.
   

Pet Cancer Therapeutics Market Share

The market is highly competitive, with the presence of key players. The companies are striving focus on expanding their product portfolios through innovations in chemotherapy, immunotherapy, and targeted treatments. In addition, strategic partnerships, acquisitions, and investments in research and development further strengthens the market positions. Furthermore, the growing demand for advanced pet cancer treatments has led to increased competition, driving innovation and the introduction of novel therapeutics to meet diverse consumer needs.
 

Pet Cancer Therapeutics Market Companies

Few of the prominent players operating in the pet cancer therapeutics industry include:

• AB Science
• Boehringer Ingelheim International
• CureLab Oncology
• Dechra Pharmaceuticals
• Elanco Animal Health
• ELIAS Animal Health
• NovaVive
• Qbiotics
• Pfizer
• Torigen
• Vibrac
• Vivesto
• Zoetis
   

Pet Cancer Therapeutics Industry News

• In August 2024, FidoCure, the flagship brand of One Health Company, received a patent from the US Patent and Trademark Office (USPTO) for an innovative targeted therapy and biomarker aimed at treating canine cancer. This novel treatment approach utilizes mutation profiling to more effectively manage bladder cancer in dogs. This advancement is expected to address the spurring demand for targeted treatments and precision medicine in veterinary oncology continues to rise.
   
• In July 2024, ELIAS Animal Health launched a new study to evaluate its adoptive T cell therapy, the ELIAS Cancer Immunotherapy (ECI). The study aimed to explore the combination of ECI with a novel adjuvant as a limb-sparing treatment for large-breed dogs diagnosed with appendicular osteosarcoma. This research marked a significant step toward advancing personalized cancer care in pets and is expected to contribute to the growing demand for novel therapies in the pet care industry.
   

The pet cancer therapeutics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Species

• Dogs
• Cats
• Other species

Market, By Therapy

• Chemotherapy
• Immunotherapy
• Targeted therapy
• Combination therapy

Market, By Route of Administration

• Oral
• Injection

Market, By Cancer Type

• Lymphoma
• Mast cell cancer
• Melanoma
• Mammary and squamous cell cancer
• Other cancer types

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE